Skip to Content

Chimerix Inc CMRX

Morningstar Rating
$1.25 +0.05 (3.73%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CMRX is trading at a 67% discount.
Price
$1.19
Fair Value
$5.87
Uncertainty
Extreme
1-Star Price
$64.42
5-Star Price
$4.57
Economic Moat
Bzpk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMRX is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.21
Day Range
$1.201.27
52-Week Range
$0.881.76
Bid/Ask
$1.23 / $1.25
Market Cap
$111.11 Mil
Volume/Avg
422,830 / 428,196

Key Statistics

Price/Earnings (Normalized)
27.47
Price/Sales
93.92
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
89

Comparables

Valuation

Metric
CMRX
HLVX
ICVX
Price/Earnings (Normalized)
27.47
Price/Book Value
0.512.763.30
Price/Sales
93.92
Price/Cash Flow
Price/Earnings
CMRX
HLVX
ICVX

Financial Strength

Metric
CMRX
HLVX
ICVX
Quick Ratio
12.5417.1217.59
Current Ratio
12.9417.5818.06
Interest Coverage
−59.70
Quick Ratio
CMRX
HLVX
ICVX

Profitability

Metric
CMRX
HLVX
ICVX
Return on Assets (Normalized)
−25.25%−30.32%−29.30%
Return on Equity (Normalized)
−27.23%−36.74%−31.87%
Return on Invested Capital (Normalized)
−31.58%−34.21%−34.69%
Return on Assets
CMRX
HLVX
ICVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXdzk$541.7 Bil
VRTX
Vertex Pharmaceuticals IncCsflwqk$111.3 Bil
REGN
Regeneron Pharmaceuticals IncPkbsrpf$109.0 Bil
MRNA
Moderna IncCjbc$36.8 Bil
ARGX
argenx SE ADRJrbts$24.3 Bil
BNTX
BioNTech SE ADRVfhw$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncVbytpd$20.0 Bil
BMRN
Biomarin Pharmaceutical IncSjqcwt$17.1 Bil
RPRX
Royalty Pharma PLC Class AZnylbrq$14.0 Bil
INCY
Incyte CorpFdlbpv$13.7 Bil

Sponsor Center